Homologous recombination deficiency and survival in ovarian high-grade serous carcinoma by self-reported race
The benefits of personalised chemo for women with ovarian cancer are obvious. However, this benefit is not being applied equally to all ethnic groups, with black women being less likely to have genetic testing and personalised chemo using PARP inhibitors.
Initially used for women with the BRCA mutation, PARP inhibitors are effective in improving survival for all women who have the metabolic defect of Homologous Recombination Deficiency (HRD).
This study compares survival for women with HRD (about 50% of all ovarian cancer), to those without. The subgroups of HRD women were divided into self-reported race. All women with HRD have a better survival chance, white women survival is improved by 62%, black women do less well with a 32% reduction in death from ovarian cancer.
The authors suggest a difference in genetic mutation for black women, who show more variations of unknown significance, and lower rates of testing, leading to disparity of care.
No comments:
Post a Comment